Patents Examined by Eric Grimes
  • Patent number: 5861298
    Abstract: The invention relates to cathepsin K polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
    Type: Grant
    Filed: May 7, 1997
    Date of Patent: January 19, 1999
    Assignees: SmithKline Beecham Corporation, Human Genome SciencesInc
    Inventors: Mark D. Adams, Judith A. Blake, Christine M. Debouck, Fred H. Drake, Lisa M. Fitzgerald, Claire M. Fraser, Maxine Gowen, Gregg A. Hastings, Ewen F. Kirkness, Norman H. Lee, Julie Rood
  • Patent number: 5861294
    Abstract: The present invention provides an adenosine kinase protein having an identified structural formula. The identified protein or similar adenosine kinase proteins having residues as claimed and recited herein may be isolated and purified from natural sources or produced by recombinant DNA technology.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 19, 1999
    Assignee: Abbott Laboratories
    Inventors: Marlon Daniel Cowart, Donald N. Halbert, James F. Kerwin, Jr., Teresa McNally
  • Patent number: 5858759
    Abstract: Processes are provided for the production of a carbamoylase enzyme which has the capability of converting a D-N-carbamoyl (optionally substituted phenyl) glycine by expressing recombinant DNA encoding a carbamoylase in a homologous host. Also provided are specific recombinant DNA vectors producing high levels of expression of the carbamoylase enzyme and/or hydantoinase enzyme in homologous and heterologous hosts and their use in the production of D-.alpha. amino acids.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: January 12, 1999
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Robert John Neal, Alison Michelle Griffin, Hazel Claire Gorham
  • Patent number: 5856122
    Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: January 5, 1999
    Assignee: University of Alberta
    Inventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
  • Patent number: 5856452
    Abstract: A method for the separation of a target molecule from a mixture is described. The method employs oil bodies and their associated proteins as affinity matrices for the selective, non-covalent binding of desired target molecules. The oil body proteins may be genetically fused to a ligand having specificity for the desired target molecule. Native oil body proteins can also be used in conjunction with an oil body protein specific ligand such as an antibody or an oil body binding protein. The method allows the separation and recovery of the desired target molecules due to the difference in densities between oil bodies and aqueous solutions.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: January 5, 1999
    Assignee: Sembiosys Genetics Inc.
    Inventors: Maurice Moloney, Gijs van Rooijen, Joseph Boothe
  • Patent number: 5854041
    Abstract: Myoglobin is shown to have Manganese (Mn.sup.2') binding and peroxidase capacity. Mn binding and peroxidase activity is enhanced by modification of the amino acid sequence of myoglobin to provide a Mn binding site on the surface of the protein near the heme group. Peroxidase activity of myoglobin not specific to Mn is enhanced by substituting amino acids at residues 39, 45, 46, 97 and 107 of myolglobin.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: December 29, 1998
    Assignee: The University of British Columbia
    Inventors: Gary D. Brayer, Hung Lee, A. Grant Mauk, Michael Smith, Harry Tong, Lianglu Wan
  • Patent number: 5851812
    Abstract: The invention provides methods and compositions relating to an I.kappa.B kinase, IKK-.beta., and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-.beta. encoding nucleic acids or purified from human cells. The invention provides isolated IKK-.beta. hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-.beta. genes, IKK-.beta.-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: December 22, 1998
    Assignee: Tularik Inc.
    Inventors: David V. Goeddel, John Woronicz
  • Patent number: 5851991
    Abstract: This invention provides a method of preventing or inhibiting the proliferation of a pathologically proliferating cell, wherein the pathological proliferation of the cell is the result of the absence of a functional retinoblastoma protein or polypeptide in the cell. The method requires contacting the cell with an effective amount of retinoblastoma protein or polypeptide. This method also is useful to prevent or treat retinoblastoma or a secondary cancer to retinoblastoma by administering to a patient a functional retinoblastoma protein or polypeptide.
    Type: Grant
    Filed: September 13, 1994
    Date of Patent: December 22, 1998
    Assignees: The Regents of the University of California, Canji, Inc.
    Inventors: Wen-Hwa Lee, Eva Y-H.P. Lee, David W. Goodrich, H. Michael Shepard, Nan Ping Wang, Duane Johnson
  • Patent number: 5849290
    Abstract: Disclosed is the family of genes responsible for the neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis. Methods and compounds for the diagnosis, prevention, and therapy of the disease are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 15, 1998
    Assignees: The General Hospital Corporation, Massachusetts Institute of Technology
    Inventors: Robert Brown, H. Robert Horvitz, Daniel R. Rosen
  • Patent number: 5849529
    Abstract: Disclosed is a cellobiose phosphorylase gene coding for a protein consisting of the amino acid sequence of SEQ ID NO: 16 as set forth in the Sequence Listing, a plasmid vector comprising the cellobiose phosphorylase gene and a transformant transformed with the plasmid vector.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: December 15, 1998
    Assignee: Director of National Food Research Institute, Ministry of Agriculture, Forestry and Fisheries
    Inventors: Kiyoshi Hayashi, Aimin Liu, Hebiao Li, Kazutomo Haraguchi, Yoshiaki Kitamura
  • Patent number: 5846824
    Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.
    Type: Grant
    Filed: January 9, 1997
    Date of Patent: December 8, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ian D. Hiles, Michael J. Fry, Ritu Dhand, Michael D. Waterfield, Peter J. Parker, Masayuki Otsu, George Panayoutou, Stefano Volinia, Ivan Gout
  • Patent number: 5846764
    Abstract: The present invention relates generally to identification of proteins, designated TIH proteins, that interact with casein kinase I isoforms and to isolation of polynucleotides encoding the same.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: December 8, 1998
    Assignee: ICOS Corporation
    Inventors: Anthony J. DeMaggio, Merl F. Hoekstra
  • Patent number: 5843718
    Abstract: Novel polyketides and novel methods of efficiently producing both new and known polyketides, using recombinant technology, are disclosed. In particular, a novel host-vector system is described which is used to produce polyketide synthases which in turn catalyze the production of a variety of polyketides.
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: December 1, 1998
    Assignees: The Leland Stanford Junior University, The John Innes Institute
    Inventors: Chaitan Khosla, David A. Hopwood, Susanne Ebert-Khosla, Robert McDaniel, Hong Fu
  • Patent number: 5843892
    Abstract: The protein, cholinergic neuronal differentiation factor (CDF), also known as leukemia inhibitory factor (LIF), is described, together with the use of the polypeptide to stimulate neuron growth and survival in animals either by direct administration or by autotransplantation of adrenal medullary cells converted to the cholinergic phenotype.
    Type: Grant
    Filed: November 18, 1993
    Date of Patent: December 1, 1998
    Assignee: California Institute of Technology
    Inventor: Paul H. Patterson
  • Patent number: 5843672
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of peptides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Jay P. Morgenstern, Andrzej Konieczny, Christine B. Bizinkauskas, Andrew W. Brauer
  • Patent number: 5843776
    Abstract: The present invention relates to a method of expressing a heterologous gene in mammalian cells and a recombinant DNA construct for use in the method. The invention also relates to a method of specifically killing cells which constitutively express AFP.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: University Technologies International, Inc.
    Inventors: Taiki Tamaoki, Hidekazu Nakabayashi
  • Patent number: 5840531
    Abstract: Cellophane wrapping (CW) of hamster pancreas induces proliferation of duct epithelial cells followed by endocrine cell differentiation and islet neogenesis. Using the mRNA differential display technique a cDNA clone expressed in cellophane wrapped but not in control pancreata was identified. Using this cDNA as a probe, a cDNA library was screened and a gene not previously described was identified and named INGAP.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: November 24, 1998
    Assignees: MoGill University, Eastern Virginia Medical School of the Medicine College of Hampton Roads
    Inventors: Aaron I. Vinik, Gary L. Pittenger, Ronit Rafaeloff, Lawrence Rosenberg, William P. Duguid
  • Patent number: 5837515
    Abstract: The structure of the T. reesei xln1 and xln2 genes and the primaru structure of proteins are described. Enzyme preparations enriched in hemicellulase enzymes are described. Such enzyme preparations may also be partially or completely deficient in cellulose degrading activity. Such preparations may be utilized in an crude, unpurified form and are especially useful in the production of pulp and paper.
    Type: Grant
    Filed: September 16, 1993
    Date of Patent: November 17, 1998
    Assignee: Alko-Yhtiot Oy
    Inventors: Pirkko Suominen, Helena Nevalainen, Ritva Saarelainen, Marja Paloheimo, Richard Fagerstrom
  • Patent number: 5837516
    Abstract: The bacterial serine protease, subtilisin BPN', has been mutated so that it will efficiently and selectively cleave substrates containing basic residues. Combination mutants, where Asn 62 was changed to Asp, Gly 166 was changed to Asp (N62D/G166D), and optionally Tyr 104 was changed to Asp had a larger than additive shift in specificity toward substrates containing basic residues. Suitable substrates of the variant subtilisin were revealed by sorting a library of phage particles (substrate phage) containing five contiguous randomized residues. This method identified a particularly good substrate, Asn-Leu-Met-Arg-Lys- (SEQ ID NO: 35), that was selectively cleaved in the context of a fusion protein by the N62D/G166D subtilisin variant. A particularly good substrate for N62D/G166D/Y104D would be Asn-Arg-Met-Arg-Lys- (SEQ ID NO: 76).
    Type: Grant
    Filed: July 19, 1995
    Date of Patent: November 17, 1998
    Assignee: Genentech, Inc.
    Inventors: Marcus D. Ballinger, James A. Wells
  • Patent number: 5834297
    Abstract: A method for the production of indigo and indirubin dyes using a recombinant Escherichia coli containing a gene encoding a phenol hydroxylase from Bacillus stearothermophilus. The dyes are used for coloring cloth and the like.
    Type: Grant
    Filed: June 16, 1997
    Date of Patent: November 10, 1998
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Patrick J. Oriel, In Cheol Kim